Updated:
KALA BIO
KALA BIO was founded in 2009 and named after a powerful Mayan sun deity, an early signal of lofty ambition for a biotech that would eventually zero in on...
KALA BIO
KALA BIO was founded in 2009 and named after a powerful Mayan sun deity, an early signal of lofty ambition for a biotech that would eventually zero in on the stubbornly difficult anterior segment of the eye. Mark Iwicki joined as CEO in 2015, inheriting a company built around a mucus-penetrating particle (MPP) technology designed to improve drug delivery to the ocular surface. Iwicki, previously a commercial lead at Novartis and Sepracor, took the firm public on Nasdaq in 2017, raising an initial $90 million with the promise of two late-stage dry eye candidates. KALA BIO's strategy has pivoted from commercial-stage ophthalmology to a purely clinical-stage focus on rare retinal diseases. The firm's first two FDA-approved products — Inveltys for post-operative inflammation and Eysuvis for dry eye disease — generated minimal traction against entrenched generic competition. By mid-2024, the company had voluntarily withdrawn both products, reversed a $75 million committed equity facility, and refocused all resources on its sole clinical asset, KPI-012, a mesenchymal stem cell secretome for persistent corneal epithelial defect (PCED). The geographic footprint is concentrated in the United States, with clinical trial sites concentrated in major ophthalmic centers like the University of Illinois Chicago. The firm has shrunk dramatically from its commercial peak. Headcount has been reduced to a skeletal clinical and corporate development team. In September 2024, KALA BIO appointed Mary Reumuth as Chief Financial Officer, succeeding a departing executive as the company navigates a cash runway that management projects into the second quarter of 2025. The company has historically funded operations through public equity offerings, debt facilities, and a 2022 forbearance agreement that required near-complete headcount reduction and the departure of its founding CEO. KALA BIO's current structural differentiator is its tenuous survival as a micro-cap public biotech stripped of commercial infrastructure. Unlike peer companies developing retinal therapies within larger, diversified pipelines, KALA BIO operates as a binary-outcome vehicle with a single asset in mid-stage development. The governance structure reflects this risk, with a classified board, a modest market capitalization hovering near $25 million as of early 2025, and a reverse stock split history that underscores the dilutive financing path required to reach its Phase 2b PCED data readout.
General information
Firm type
Asset Manager
Year founded
2009
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Arlington
Corporate office
Arlington, MA, United States
Principals
Mark Iwicki
Chairman, President and Chief Executive Officer
Sector focus
Frequently asked questions
What led KALA BIO to withdraw its two FDA-approved products?
Inveltys and Eysuvis failed to achieve commercially meaningful market penetration against low-cost generic steroid drops and over-the-counter artificial tears. The company's commercial infrastructure consumed cash that management determined was better allocated to clinical development, leading to voluntary withdrawal of both product applications by mid-2024.
What is KPI-012 and why is it the company's sole remaining asset?
KPI-012 is a human mesenchymal stem cell-derived secretome being investigated for persistent corneal epithelial defect, a rare condition where the cornea fails to heal. The molecule earned orphan drug designation from the FDA. Management placed the company's future entirely on KPI-012 after a strategy review concluded the dry eye commercial business was unsalvageable.
How is KALA BIO funding its operations with no approved products?
The company relies on periodic public equity offerings and at-the-market sales of common stock. A $75 million committed equity facility originally secured in 2021 was amended downward and terminated by late 2024, leaving the firm dependent on its existing cash reserves and future dilutive financings to reach the next clinical data milestone.
Who makes the key strategic decisions given the company's small board?
CEO Mark Iwicki holds a tightly consolidated governance structure as Chairman, President, and CEO. The board of directors includes veteran biotech operator Gregory Perry and Deepa Pakianathan, a managing member at Delphi Ventures, reflecting the venture-capital roots that seeded the company's original nanoparticle platform.
What happened during the 2022 debt restructuring?
KALA BIO entered a forbearance agreement with its lender after breaching minimum revenue covenants tied to its commercial portfolio. The restructuring forced the company to cut its workforce by nearly half, eliminate its founding CEO, and renegotiate payment terms. This event marked the beginning of the strategic retreat from commercial ophthalmology.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: